Quarterly ResultAug 12, 2026, 06:37 AM
Unicycive H1 2026 Net Loss $(14.5M); Cash $44.2M; Raises $34M
AI Summary
Unicycive Therapeutics reported a net loss of $(14.5) million for the six months ended June 30, 2026, compared to a net loss of $(5.9) million in the prior year period. The company significantly increased its cash and cash equivalents to $44.2 million as of June 30, 2026, up from $29.2 million at December 31, 2025. This increase was primarily driven by net proceeds of approximately $34.0 million from the sale of common stock through a sales agreement. Unicycive continues to incur operating losses as it develops its drug candidates, UNI 494 and Renazorb, but believes it has sufficient resources for at least one year.
Key Highlights
- Net loss for H1 2026 was $(14.5) million, up from $(5.9) million in H1 2025.
- Cash and cash equivalents increased to $44.2 million as of June 30, 2026.
- Raised $34.0 million net from common stock sales in H1 2026.
- Total assets grew to $72.0 million from $49.1 million at year-end 2025.
- Total stockholders' equity increased to $53.3 million.
- Net loss per share (diluted) was $(0.57) for H1 2026.
- R&D expenses rose to $4.4 million in H1 2026 from $3.9 million.
- G&A expenses increased to $14.2 million in H1 2026 from $11.0 million.
Price Impact
More from UNCY